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Abstract Gastrointestinal mucositis is a complex inflamma-
tory reaction of the mucous membranes, a side effect of both
chemotherapy and radiotherapy. Currently, assessment scales
are used to diagnose mucositis. However, a biomarker which
would determine whether there is mucositis and thereby es-
tablish the severity objectively would be very useful. This will
give the opportunity to evaluate studies, to determine risk
factors and incidence, and it will make it possible to compare
studies. Moreover, this biomarker might improve clinical
management for patients. In this paper, we reviewed studies
concerning potential biomarkers in blood samples and fecal
samples, and potential tests in breath samples and urine sam-
ples. We include biomarkers and tests studied in animal
models and/or in clinical trials, and discuss the validity, diag-
nostic accuracy, and applicability.
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Introduction
Mucositis is a severe side effect of both chemotherapy and
radiotherapy in several cancer treatment protocols. It com-
prises complex inflammatory damage to the mucosa of the
complete alimentary tract. Gastrointestinal mucositis, further
referred to as mucositis, is complex and the pathophysiology
can be based on the five-phase pathophysiological model of
oral mucositis [1, 2]. However, the exact working mechanism
has not been elucidated. Patients suffer from abdominal pain,
vomiting, and diarrhea, with consequently weight loss, nutri-
tional support, and an increased risk to develop a sepsis or
bacteremia [3, 4].The incidence of mucositis is estimated at
40–100% of patients with chemotherapy, dependent of treat-
ment and patient-related factors [4, 5]. The estimation of the
incidence is such a broad range, since there is no gold standard
for diagnosis and assessment of the severity of mucositis. The
therapy of cancer has been changed in the past years to more
targeted therapies. However, the effect of these targeted ther-
apies on the risk, severity, and incidence of mucositis is un-
known. It is thought that there is an underreporting of muco-
sitis due to a lack of a gold standard [6]. Ideally, for the diag-
nosis and severity of mucositis, inspection of the small intes-
tine microscopically would be necessary. Therefore, the gold
standard would be a biopsy from the small intestine. However,
an endoscopy is invasive, can be painful, the small intestine is
only visible for a small part, and moreover, this test is not
preferable in an immune-compromised patient since there is
a high risk of infection and bleeding. The intestinal tissue is
vulnerable during mucositis. Therefore, clinical practice is in
need of a test to diagnose and assess the severity of mucositis.
An optimal test to diagnose mucositis and establish the sever-
ity will give the opportunity to evaluate studies, to determine
risk factors and incidence, and if used in all studies, it will
make it possible to compare them. Moreover, this optimal test
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will potentially improve management in for example prophy-
lactic antibiotic use, or diet changes for nutritional support.
The clinical way to determine the severity of mucositis to
date is the use of an assessment scale. There are a few assess-
ment scales developed to determine the severity of mucositis,
like the National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) scale and the
Daily Gut Score (DGS) [3, 7, 8]. These scoring scales are
based on several aspects like vomiting, diarrhea, pain, abdom-
inal complaints, and nutritional support. Moreover, several
hospitals have developed their own assessment scale for mu-
cositis; the use of these many different scales makes it difficult
to compare studies and improve the clinical practice. More
importantly, these assessment scales are subjective, based on
symptoms not very specific for mucositis, influenced by pain
relief medication, and have not been validated for the use in
young children [3]. Therefore, a biomarker which would de-
termine whether there is mucositis and thereby establish the
severity objectively would be very useful. Several potential
biomarkers and tests have been studied, both preclinical and
clinical. In a few reviews about biomarkers, several possible
biomarkers were already discussed. [9–12]. In this review, we
give an update including new studies from recent years
concerning potential biomarkers in blood samples and fecal
samples, and potential tests in breath samples and urine sam-
ples. We include biomarkers and tests studied in animal
models and/or in clinical trials.
Definition of biomarker
The terminology around biomarkers is broad. The question is
when is a measured sample a biomarker? The Biomarkers
Definition Working Group mentioned a biomarker as Ba char-
acteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic process-
es, or pharmacologic responses to a therapeutic intervention^
[13]. Another, more specific recommendation for a definition
was Bhuman or animal biological property whose in vitro
measurement or identification is useful for the prevention,
diagnosis, prognosis, treatment, and follow-up of human or
animal diseases, and for their understanding^ [14]. In this
review, we will use this second definition. In respect to muco-
sitis, a biomarker should diagnose mucositis and should de-
termine the severity of mucositis. Moreover, this biomarker
should be easily accessible, non-invasive, and sequentially
determinable. This means in our opinion that a biomarker
should be present in the human body without adding some-
thing from outside the body to measure a response. In other
words, this biomarker is present in healthy individuals and is
altered, either higher or lower, due to mucositis. We interpret
the use of a substitute that has to be administered to the patient
in any way more as a test to determine the severity of damage
to the mucosa. Therefore, we make a division in biomarkers,
which are actually present in the body, and tests, which need
the administration of any kind of substrate to the patient before
measurement. To evaluate the usefulness of a biomarker or
test in the diagnosis of a disease, three aspects should be in-
cluded. First, the validity of the biomarker or test shows if the
result matches the severity of the disease and whether it clas-
sifies the patient correctly. Second, the diagnostic accuracy
determines the chance that a patient with a positive test or
biomarker has the disease, and the chance that a patient with
a normal biomarker of test has the disease. Finally, the appli-
cability values if the biomarker or test is feasible and cost
effective in the specific patient group. Therefore, in this re-
view, we value all biomarkers and tests for mucositis on these
three points: the validity, the diagnostic accuracy, and the ap-
plicability, although this is challenging due to the absence of a
gold standard.
Potential biomarkers in blood samples
Citrulline
One of the most significant potential biomarkers for mucositis
is citrulline in blood samples, measurable in both serum and
plasma. The intestine is the primary source for the amount of
citrulline present in the blood circulation [15]. Citrulline is a
non-protein amino acid, synthesized almost exclusively by the
enterocytes of the small intestine. It is synthesized in the
enterocyte from glutamine, and only released in the circulation
as a masked form of arginine, to bypass the uptake of arginine
by the liver, and to be converted back to arginine in the kid-
neys [11]. In fact, citrulline is an intermediary product of ami-
no acid metabolism [16]. Crenn et al., showed that plasma
citrulline correlates with the small bowel length, and that it
is a potential biomarker of small intestinal enterocyte mass in
patients with celiac disease [16, 17]. Moreover, in more than
500 patients suffering from several intestinal diseases, plasma
citrulline was shown as biomarker for the enterocyte mass
reflecting the absorptive capacity of the small intestine [18].
Lastly, citrulline has been shown not to be influenced by in-
flammation or by the nutritional intake, since diet seems to be
a poor source of citrulline [11, 18, 19]. Unfortunately, plasma
citrulline level cannot be used as biomarker in case of renal
failure if creatinine clearance is below 50 ml/min, since this
increases the citrulline level in the blood [18, 20] (in clinical
practice, probably a creatinine clearance below 30 ml/min is
relevant, personal experience).
Citrulline can be accurately measured in little volumes,
even in 30 μl. It is measured by automated ion exchange
column chromatography [21, 22]. During mucositis, the
enterocyte mass significantly decreases. Therefore, citrulline
is expected to decrease during mucositis, which represents the
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enterocyte mass and thereby, the absorptive capacity during
mucositis. Therefore, several studies have been performed to
determine plasma or serum citrulline as a possible marker for
mucositis.
In preclinical studies, it was shown that plasma citrulline
correlates significantly with the villus length in a
methotrexate-induced mucositis rat model [23]. Furthermore,
preclinical studies showed that the use of plasma citrulline
corresponded with radiation-induced mucositis in rats and
mice [24, 25]. Even more, plasma citrulline correlated with
the digestion and absorption of lactose and fatty acids during
mucositis in rats [23, 26].
One of the first clinical studies concerning the possibility of
plasma citrulline as biomarker was determined by Blijlevens
et al., [27]. It was shown that low serum citrulline levels
corresponded with severe mucosal barrier injury, measured
with the daily gut score and sugar permeability test, in patients
receiving hematopoietic stem cell transplantation [27, 28].
Furthermore, it was also determined that serum citrulline
levels decreased during radiotherapy, correlating with the se-
verity of mucositis, making it also suitable in radiotherapy-
induced mucositis [29]. In 2009, plasma citrulline was com-
pared with several other methods to diagnose mucositis, like
the NCI-CTCAE mucositis scoring scale, daily gut score,
plasma interleukin-8, fecal interleukin-8, fecal calprotectin,
and the sugar absorption test in pediatric cancer patients with
GI mucositis [30]. The authors showed that of all parameters,
plasma citrulline correlated the strongest with the daily gut
score and the NCI-CTCAE scale, and possibly can even detect
mucositis if it is not clinically overt [30]. In adult HSCT pa-
tients, bacteremia coincided with low plasma citrulline levels
[31]. Furthermore, it has been suggested to use a citrulline
based assessment score [32]. In 2013, Van der Velden and
colleagues investigated the use of plasma citrulline and albu-
min as a possible biomarker for mucositis in adult patients
receiving hematopoietic stem cell transplantation [33]. They
concluded that plasma citrulline is the most potent biomarker;
it might be useful in the clinical decision making, for thera-
peutic interventions or nutritional support [33]. In another
pilot study, the authors also showed that serum citrulline is
decreased after the conditioning regimen for HSCT in adult
patients due to intestinal damage [34]. A more recent study
determined the value of citrulline as biomarker in pediatric
patients receiving HSCT [35]. They concluded that serum
citrulline correlated with gastrointestinal function, determined
with a combination of oral mucositis score, pro-inflammatory
cytokines, oral intake, bodyweight change, and graft-versus-
host disease, in children undergoing HSCT [35].
In the past years, a few reviews concerning biomarkers
for mucositis were published [9, 10, 12]. A more detailed
review about citrulline as biomarker for mucositis was
published in 2014 by Barzal et al. [11]. We conclude that
citrulline is a biomarker of mucositis, based on the
abovementioned definition. It correlates with the severity
of mucositis and is sequentially detectable; therefore, the
applicability and validity of citrulline seems good.
However, we cannot draw any conclusions about the di-
agnostic accuracy, because more research is needed to
answer these questions.
Cytokines
In the pathophysiology of mucositis, which is not yet
completely elucidated, pro-inflammatory cytokines like
TNF-α, IL1-beta, and IL-6 are important. Increased levels of
cytokines are determined during mucositis in both animal
models and clinical trials [36, 37]. Therefore, these cytokines
are also a potent biomarker for mucositis. These pro-
inflammatory cytokines represent the inflammatory part of
the mucositis pathophysiology.
One of the major concerns for the use of cytokines as bio-
marker is that the determination of cytokines during mucositis
is critically time dependent [38]. However, Bowen et al. de-
termined in a pilot study in patients with esophageal cancer,
treated with both chemotherapy and radiotherapy, the value of
pro-inflammatory genes as predictive value. They concluded
that mRNA of TNF-α was consistently increased in the pa-
tients suffering from gastrointestinal toxicity [39]. However,
this was only a small sample size in a specific patient group,
and moreover, they studied gastrointestinal toxicity in general,
of which one was mucositis. Furthermore, in pediatric oncol-
ogy patients, interleukin-8 (IL-8) only correlated with the dai-
ly gut score and the NCI-CTCAE scale in patients with febrile
neutropenia [30]. Furthermore, as shown in other studies, IL-8
is effective for determining febrile neutropenia [40, 41].
Therefore, IL-8 is probably useful in determining infections
in general.
Mucositis is a risk factor to develop fever; however, febrile
neutropenia might be induced by another infection. The im-
portance of neutrophils in the initiation of mucositis is un-
known [42]. Even more, fever is often present during mucosal
barrier injury with or without an infection, due to the fact that
there is an immune response irrespective of the presence of
any particular microbial pathogen [43]. Thus, in general, pa-
tients with mucositis are mostly complex patients with neu-
tropenia, fever, and other causes of inflammation, for example
graft-versus-host disease. This gives the most important dis-
advantage of the use of these cytokines as biomarkers; cyto-
kines are non-specific for mucositis, but may reflect any in-
flammation present in the body. Due to too much influence of
other mechanisms, the validity and diagnostic accuracy are
low; cytokines are a non-specific marker for inflammation.
Therefore, inflammatory cytokines like TNF-α does not seem
to be suitable as a biomarker for mucositis, according to the
biomarker definition mentioned above.
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C-reactive protein
C-reactive protein (CRP) is used in clinical practice as an
acute phase protein increased in case of an inflammation.
During mucositis, there is inflammation in the intestine, sug-
gesting to increasing the CRP in the blood. However,
Miedema et al. determined that CRP increases only late after
onset of fever and concluded that it is a late marker for febrile
neutropenia [40]. This is probably also the case for mucositis.
Moreover, as already mentioned for the pro-inflammatory cy-
tokines, the validity and diagnostic accuracy of CRP are low,
since it is also influenced by many other inflammatory mech-
anisms often present in the patient suffering from mucositis,
like infections. Therefore, CRP is probably not a valuable
biomarker for mucositis.
Intestinal fatty acid binding protein and ileal-bile acid
binding protein
Intestinal fatty acid binding protein (I-FABP), an endogenous
cytosolic enterocyte protein, and ileal bile acid binding protein
(I-BABP), present in enterocytes, are both released by dying
mature enterocytes and therefore possible markers of
enterocyte loss in the small intestine. I-FABP has been shown
to be a possible useful plasma marker for intestinal injury
shown in human tissue samples and blood samples [44].
Furthermore, I-FABP has been shown to be a possible system-
ic marker for Crohn’s disease [45]. In 2009, Derikx and col-
leagues showed in patients receiving conditioning regimen for
HSCT that citrulline in combination with I-FABP and I-BABP
possibly assess not only the enterocyte mass but also the
enterocyte turnover in the small intestine [28]. No further
studies with I-FABP or I-BABP in other animal experiments
or clinical trials during mucositis have been performed.
Therefore, no conclusions can be drawn concerning the valid-
ity, diagnostic accuracy, and applicability. In respect to the
definition of a biomarker for mucositis, these markers need
further research to draw any conclusion; however, these pro-
teins might be potentially useful.
Potential biomarkers in feces samples
Granulocyte marker proteins
Fecal calprotectin and calgranulin (S100A12) are granulo-
cyte marker proteins which are possible markers of intes-
tinal inflammation [46]. Calprotectin in fecal samples has
been used in many diseases concerning inflammation in
the intestine. In a clinical trial with many patients with
several intestinal inflammatory disorders, it was shown
that fecal calprotectin levels were increased compared to
healthy controls [47, 48]. Fecal calgranulin (S100A12) has
also been shown to be a marker for inflammatory bowel
disease [46]. Therefore, granulocyte marker proteins seem
to be reliable markers of intestinal inflammation. During
mucositis, there is indeed inflammation in the intestine.
However, in cont ras t to animal models , dur ing
chemotherapy-induced mucositis in humans, there is often
neutropenia; there is no influx of myeloid cells. Since there
is neutropenia in most of the patients suffering from mu-
cositis, calprotectin and calgranulin will not be increased in
these patients. This has been shown in a small study with
pediatric cancer patients, where fecal calprotectin was un-
detectable in most samples, probably due to the fact that
these patients were neutropenic [30]. Therefore, during
chemotherapy-induced mucositis, calprotectin and
calgranulin are probably not useful biomarkers. However,
the granulocyte marker protein has been shown to be a
possible marker during radiation-induced mucosal damage
in rats [49]. Patients receiving radiation and suffering from
mucosal damage are most of the times not neutropenic;
therefore, calprotectin or calgranulin might indeed be a
possible biomarker for these specific patients [50, 51].
Therefore, for these biomarkers, there should be a division
between radiation-induced mucositis and chemotherapy-
induced mucositis. Currently, no conclusions can be drawn
concerning the validity, diagnostic accuracy, and the appli-
cability. Fecal calprotectin or fecal calgranulin might be a
biomarker for radiation-induced mucositis, but we are in
need of clinical trials to draw any conclusion.
Ratio fecal human DNA/total DNA
Another possible biomarker in feces samples is the ratio fecal
human DNA/total DNA. With this ratio, the loss of
enterocytes can be measured. This ratio was studied as a pos-
sible biomarker in pediatric cancer patients suffering from
mucositis. Van Vliet et al. showed no significant increase in
the ratio during mucositis; however, the fecal DNA ratio did
correlate with both the DGS and the NCI-CTCAE criteria in
pediatric cancer patients [30]. So the ratio fecal human DNA/
total DNAmight indicate loss of enterocytes duringmucositis;
however, no further research has been performed. The fecal
DNA ratio is a possible marker for mucositis, but no conclu-
sions can be drawn concerning the validity, diagnostic accu-
racy, and applicability without further research.
Potential tests of intestinal damage in urine or breath
samples
Sugar permeability test
The sugar permeability test was developed to test the gut
barrier function using a non-invasive method. For this
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test, the patient has to ingest a hypertonic solution with
monosaccharide, like L-rhamnose, and disaccharide, like
lactulose, sugars which are not metabolized. Mono
saccharides represent the transcellular route of absorption,
and disaccharides represent the paracellular route of ab-
sorption. These sugars are almost unchanged excreted in
the urine. Therefore, the measured levels in urine repre-
sent the permeability of the gut, where monosaccharides
represent the absorption surface area and disaccharides
represent the permeability of tight junctions of the small
intestine [52].
In adult HSCT patients, this sugar permeability test has
shown that these patients had abnormal permeability of the
gut for both sugars [53]. In another study, the sugar perme-
ability test showed a decrease in sugars in urine [27].
However, for the sugar permeability test, urine collection dur-
ingmultiple hours is necessary [9, 10]. Van vliet et al. included
the sugar permeability test in a clinical trial in pediatric cancer
patients to compare several tests and biomarkers for mucositis.
However, sugar intake and urine collecting was problematic in
pediatric cancer patients due to vomiting and severe diarrhea
[30].
Previously in a review about non-invasive biomarkers for
mucositis, it was already concluded that the sugar permeabil-
ity test may describe the barrier function, but does not neces-
sarily determine the absorptive capacity of the small intestine
[10]. No new studies have been conducted in the last years.
This test might be potential to determine the barrier function
of the small intestine during mucositis. However, this is not a
biomarker, according to the abovementioned definition, but it
might be a possible useful test to show the effect of the
ingested sugars. Currently, no conclusions can be drawn
concerning the validity, diagnostic accuracy, and applicability.
Hydrogen breath test
The hydrogen breath test is based on the principle that sugars
in the small intestine are malabsorbed in a damaged intestine.
This causes a consequently increased amount of sugars in the
colon which are metabolized by bacteria producing hydrogen.
This hydrogen reaches, via the bloodstream, the lungs and is
expired in the breath. Therefore, a damaged intestine will the-
oretically increase the hydrogen in the breath [12]. However,
this test does not only result from malabsorption of sugars in
the small intestine, but is also a result from the presence of
certain bacteria in the colon as mentioned in other reports [10,
12, 54]. Moreover, the hydrogen breath test is mostly used for
bacterial overgrowth [55, 56]. During mucositis, the bacteria
in the intestine are altered by multiple factors like diet and
medication, especially antibiotics. Moreover, the bacteria
might influence all phases of the pathophysiology of mucosi-
tis [57]. Therefore, the hydrogen breath test has a low validity
and diagnostic accuracy, and is probably not a suitable test for
gastrointestinal mucositis.
13clactose breath test
For the 13Clactose test, the lactose has to be ingested and this
will be digested in the small intestine by lactase, then metab-
olized in the liver and expired via the breath [12]. The
13Clactose breath test combined with the hydrogen breath test
was shown to be more effective to determine mucosal damage
than the hydrogen breath test alone [12, 58]. However, for the
13c lactose breath test, intestinal lactase is the most important
factor, and it has been shown that a lot of people normally
have low lactase activity [10, 58]. Therefore, the 13c lactose
breath test is not a suitable marker for mucositis, because the
validity, diagnostic accuracy, and applicability are all low.
Sucrose breath test
One of the possible tests is the 13C-sucrose breath test (SBT).
For the SBT, patients have to ingest 13C-sucrose. This will be
digested in the intestine by sucrase, in the liver metabolized,
and eventually expired in the breath [10]. Therefore, SBT
seems to be a possible marker for digestive enzymes and
enterocytes in the small intestine, an indicator for small bowel
function [10]. Mucositis is a complex mechanism, but one of
the clear features is villus atrophy in the small intestine, with a
consequently decreased absorption area and a decreased
amount of digestive enzymes. Therefore, the SBT is a poten-
tial test to determine the severity of mucositis and will show a
decreased amount of 13CO2 in the expired breath if there is
damage to the intestine. A few studies in animal models have
shown that SBT is a possible marker for mucositis [59–62].
Tooley et al. performed a small clinical trial in pediatric cancer
patients, and concluded that SBT possibly non-invasively de-
tect gut damage [63]. However, this was a small sample size
[64]. Furthermore, so far, this is the only clinical trial per-
formed with SBT during mucositis. To measure the SBT,
breath samples have to be taken every 15 min during a few
hours, multiple times during admission [9, 12]. This is for the
pediatric cancer patients really invasive and difficult for the
very young children. However, this test was feasible in chil-
dren with diarrhea, not cancer treatment related, where the
SBT value was significantly decreased compared to healthy
control, suggesting a decreased absorption capacity [65]. The
current knowledge shows a promising validity, an unknown
diagnostic accuracy, and conflicting findings concerning the
applicability. Therefore, more clinical trials are needed to
draw conclusions about the validity, diagnostic accuracy,
and applicability of this SBT during mucositis and thereby
to determine whether it is a potential test to diagnosemucositis
(Table 1).
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Discussion
In this review, we had a critical view, based on the validity, the
diagnostic accuracy, and the applicability, on several studied
biomarkers and tests to diagnose mucositis and assess the
severity. As mentioned above, we made a division in bio-
markers, which are actually present in the body, and tests,
which need the administration of any kind of substrate to the
patient before measurement.
At first, we can conclude that potential biomarkers in blood
samples like cytokines and CRP are not specific enough for
mucositis, since there is too much influence of other inflam-
matory mechanisms like infections; therefore, these parame-
ters are probably not useful as a biomarker for mucositis, in
agreement with a previous review about biomarkers [9]. In
contrast, the markers I-FABP and I-BABP in blood samples
are indeed potentially interesting biomarkers since they are
released by dying mature enterocytes; therefore, I-FABP and
I-BABP are potential markers of enterocyte loss in the small
intestine. However, the determination of these markers is
probably critically time dependent and only of value in com-
bination with another biomarker like citrulline for example,
but further research is needed. Furthermore, in blood samples,
plasma citrulline is in our opinion one of the most promising
biomarker. Several studies have shown that citrulline is mea-
surable in animal models, adult patients, and pediatric pa-
tients. It is easily detectable, sequentially measurable, and
might even detect mucositis if it is not clinically overt [30].
In addition to the blood samples, the use of feces samples to
measure a biomarker is interesting due to the non-invasiveness
for the patient. We can conclude that the biomarkers in feces,
like calprotectin and calgranulin, are promising to detect in-
testinal inflammation, but probably not useful in neutropenic
patients. However, during radiation-induced mucositis, they
Table 1 Potential biomarkers and tests
Potential biomarker Advantages Disadvantages
Blood
Citrulline Marker for enterocyte mass
Sequentially detectable
Correlates with mucosal damage in animal models
and clinical trials
Not useful in renal failure (if creatinine clearance is <50 ml/min)a
Cytokines Correlates with inflammation Non-specific marker for inflammation
C-reactive protein Correlates with inflammation Non-specific marker for inflammation
Late marker, increases after fever
I-FABP Enterocyte turnover in combination with citrulline Short half-life time
Only of value in combination with citrulline
I-BABP Enterocyte turnover in combination with citrulline Short half-life time
Only of value in combination with citrulline
Feces
Granulocyte marker
proteins
Correlate with leucocyte count Not useful during neutropenia
Calprotectin Correlates with inflammation Not detectable during neutropenia, not useful in most patients with
chemotherapy-induced mucositis
Calgranulin (S100A12) Correlates with inflammation Not detectable during neutropenia, not useful in most patients with
chemotherapy-induced mucositis
Ratio fecal human
DNA/total DNA
Marker for enterocyte loss Time consuming, less useful in acute clinical phase
Potential tests
Urine
Sugar permeability test Non-invasive No direct measurement: collection of urine during longer duration
Not absorptive measurement
Breath
Hydrogen breath test Simple Dependent on certain bacteria in colon
Time consuming
Lactose breath test Simple Low lactase activity➔ only useful in small percentage of patients
Time consuming
Sucrose breath test Correlates with mucosal damage in the small
intestine in animal experiments
One study shows correlation in children
Invasive: multiple breath samples during hours
Specialized equipment
a In clinical practice, probably a creatinine clearance below 30 ml/min is relevant, personal experience
Support Care Cancer
are indeed promising and more research is needed.
Furthermore, the ratio fecal human DNA/total DNA is also
interesting and more research is needed. However, it is really
time consuming to determine this ratio and therefore probably
less useful as biomarker in the acute clinical phase.
Besides possible biomarkers present in the body, the use of
a non-invasive test to determine mucositis is also promising.
The sugar permeability test seems interesting to show the bar-
rier function of the gut; however, in the recent years, no new
studies have been performed. Other possible tests, like the
hydrogen breath test and the lactose breath test, are probably
not useful, since it is dependent on either certain bacteria or
lactase in the intestine. In comparison, the SBT seems to be
superior compared to the hydrogen breath test and the
13Clactose breath test as a possible biomarker of mucositis,
as concluded previously [12]. However, although breath sam-
ples are non-invasive, due to the multiple times and long du-
ration especially for children, this test is indeed invasive.
Moreover, specialized equipment is necessary. Therefore, for
the SBT, more clinical trials are necessary to draw any con-
clusion about the feasibility during mucositis and thereby
about the usefulness.
A few studies compared several biomarkers and tests to
diagnose and determine the severity of mucositis. Lutgens
et al. compared the use of the sugar permeability test with
citrulline for the measurement and monitoring of treatment-
related gut damage and concluded that citrulline assay is the
first choice and objective parameter [66]. Furthermore, citrul-
line and the sugar permeability test were studied in adult
HSCT patients and citrulline was concluded to correlate the
best with intestinal damage determined with the DGS score
[27]. Evenmore, Van Vliet et al. compared several biomarkers
and tests, like citrulline, IL-8, fecal calprotectin, and sugar
permeability test, in pediatric cancer patients and concluded
that citrulline correlated the strongest with the severity of mu-
cositis based on assessment scores [30]. Moreover, in that
study, fecal calprotectin was not detectable due to the absence
of neutrophils, and the sugar permeability test was not feasible
due to diarrhea and vomiting.
Furthermore, it was shown that there is a possible influence
of entero-endocrine hormones, like glucagon-like-peptide 1
(GLP-1) and glucagon-like-peptide 2(GLP-2), in the patho-
physiology of mucositis. We speculate that future studies
should determine the usefulness of one of these hormones as
a biomarker for mucositis [67].
In conclusion, mucositis is still challenging to diagnose,
since the gold standard biopsy of the small intestine in not
optional. Many different methods to establish the diagnosis
and determine the severity of mucositis in both adult and pe-
diatric clinical oncology settings are currently used. This
makes any comparison about the diagnosis and thereby about
the risk, the incidence, and the severity challenging.
Moreover, what are the parameters in either a clinical trial or
animal experiment to answer the question if a prevention or
therapy is effective?We are in need of a biomarker or test to be
able to diagnose mucositis in the clinical setting and thereby
determine the severity. Second, we are in need of a biomarker
or test to improve the animal experiments and clinical trials for
new insights in preventive and therapeutic strategies. If we
have a standardmethod to diagnosemucositis, we can actually
compare studies for the incidence and severity of mucositis in
several different clinical settings. Even more, in clinical trials,
we can study a prevention or treatment in patients of which we
are certain that they have mucositis determined by a standard
biomarker or test. In this way, we are not studying an inter-
vention in the complete population, which will prevent unnec-
essary treatment of patients who will not develop mucositis.
Probably this will not be possible with only one biomarker; we
are possibly in need of a combination of biomarkers or tests.
We conclude that plasma citrulline seems to be one of the most
promising biomarkers to date, and we suggest to use this bio-
marker in future clinical trials and animal experiments. More
research is needed to find a combination of biomarkers or tests
to determine non-invasively, sequentially mucositis and its
severity.
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